ANAB - アナプティスバイオ （AnaptysBio Inc.） アナプティスバイオANABのチャート
ANABの企業情報
| symbol | ANAB |
|---|---|
| 会社名 | AnaptysBio Inc （アナプティスバイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アナティスバイオ(AnaptysBio Inc.)は米国の生物技術会社である。同社は炎症および免疫腫瘍学における満たされていない医療ニーズに焦点を当てた抗体製品候補の開発に従事する。同社は、抗体産生の自然過程をインビトロで複製するように設計された抗体発見技術プラットフォームを使用して、その製品候補を開発する。その製品パイプラインには、未治療の医療ニーズを伴う重度の炎症性障害を治療するために開発されているANB020とANB019が含まれる。ANB020製品候補は、インターロイキン-33の活性を阻害する抗体であり、重度の成人喘息および重度の成人のピーナッツアレルギーの治療に使用される。同社は、一般化した膿疱性乾癬（GPP）および掌蹠膿疱性乾癬（PPP）と呼ばれる稀な炎症性疾患の治療のために、インターロイキン36受容体を阻害する抗体ANB019製品候補の開発に従事する。 アナプティスバイオは米国のバイオ医薬品企業。臨床段階で、炎症の治療に関連する抗体医薬品の開発に従事。同社は体細胞超変異を用いる抗原結合物質を生成するプラットフォ―ムを開発、試験管内で抗体生成のプロセスを再現する。医療ニ―ズはあるが治療法がまだない炎症の分野に専念する。本社所在地はカリフォルニア州サンディエゴ。 Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne. |
| 本社所在地 | 10421 Pacific Center Court Suite 200 San Diego CA 92121 USA |
| 代表者氏名 | Hamza Suria ハムザスリア |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 858-362-6295 |
| 設立年月日 | 38657 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2017年 |
| 従業員数 | 60人 |
| url | www.anaptysbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/anab |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -46.19900 |
| 終値（lastsale） | 90.395 |
| 時価総額（marketcap） | 2172774988.145 |
| 時価総額 | 時価総額（百万ドル） 2284.503 |
| 売上高 | 売上高（百万ドル） 3.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 228.214 |
| 当期純利益 | 当期純利益（百万ドル） -37.06000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AnaptysBio Inc revenues decreased from $7M to $0K. Net loss increased from $14.1M to $28.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 45% to $20.7M (expense) General and administrative - Balancing increase of 60% to $4.6M (expense). |
ANABのテクニカル分析
ANABのニュース
AnaptysBio Inc. (NASDAQ:ANAB) -3.56% Down Over Last Week, What Happens Next? 2023/01/28 13:30:00 Marketing Sentinel
In last trading session, AnaptysBio Inc. (NASDAQ:ANAB) saw 0.68 million shares changing hands with its beta currently measuring -0.11. Company’s recent per share price level of $24.11 trading at -$0.3 or -1.23% at ring of the bell on the day assigns it a market valuation of $669.05M. That closing price of ANAB’s stock is at … AnaptysBio Inc. (NASDAQ:ANAB) -3.56% Down Over Last Week, What Happens Next? Read More »
AnaptysBio Inc. (ANAB) Forecast: Revisiting The Past To Gain Insights For The Future 2023/01/27 15:00:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) concluded the trading at $24.41 on Thursday, January 26 with a fall of -1.97% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $24.90 and 5Y monthly beta was reading -0.03 with its price kept floating in the range … AnaptysBio Inc. (ANAB) Forecast: Revisiting The Past To Gain Insights For The Future Read More »
Investing in AnaptysBio Inc. (ANAB) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/24 13:32:00 US Post News
As of Monday, AnaptysBio Inc.’s (NASDAQ:ANAB) stock closed at $25.13, up from $25.00 the previous day. While AnaptysBio Inc. has overperformed by 0.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ANAB fell by -19.22%, with highs and lows ranging from $34.33 to $18.20, whereas the […]
AnaptysBio Inc. (ANAB) deserves closer scrutiny 2023/01/16 18:24:00 US Post News
As of Friday, AnaptysBio Inc.’s (NASDAQ:ANAB) stock closed at $26.38, up from $23.07 the previous day. While AnaptysBio Inc. has overperformed by 14.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ANAB fell by -24.09%, with highs and lows ranging from $35.22 to $18.20, whereas the […]
AnaptysBio rises 10% on stock repurchase of up to $50M 2023/01/13 14:39:47 Seeking Alpha
AnaptysBio (ANAB) said it had authorized a stock repurchase plan under which it can repurchase up to $50M common stock for $0.001 per share. (ANAB) rose ~10%. The company also…
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference 2022/08/05 20:00:00 GlobeNewswire
SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022, at 3:30 p.m. ET / 12:30 p.m. PT.
AnaptysBio Inc. (NASDAQ: ANAB) Stock Seems Like A Good Option 2022/06/25 12:00:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) shares, rose in value on Friday, 06/24/22, with the stock price up by 2.21% to the previous day’s close as strong demand from buyers drove the stock to $23.12. Actively observing the price movement in the last trading, the stock closed the session at $22.62, falling within a range of $22.18 and … AnaptysBio Inc. (NASDAQ: ANAB) Stock Seems Like A Good Option Read More »
An Analysis Of AnaptysBio Inc.’s (ANAB) Stock Behavior 2022/06/11 14:30:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) concluded the trading at $22.00 on Friday, June 10, with a fall of -3.17% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $22.72 and 5Y monthly beta was reading 0.13 with its price kept floating in the range … An Analysis Of AnaptysBio Inc.’s (ANAB) Stock Behavior Read More »
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference 2022/06/02 20:05:00 GlobeNewswire
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Dan Faga, chief executive officer, and Paul Lizzul, chief medical officer of AnaptysBio, will represent the company in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 10:00 a.m. ET / 7:00 a.m. PT.
Short Volatility Alert: AnaptysBio, Inc. 2022/05/26 15:12:27 Benzinga
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB ) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment for ANAB has been Bearish. The signal from the volatility alert is trending Bearish . Therefore, the recommendation is to Strong Sell. The volatility alert was produced on the prior trading date, 5/25/2022, with a volatility change of +33.90%. The current volatility indicator stands at 7.237. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the … Full story available on Benzinga.com
Short Volatility Alert: AnaptysBio, Inc. 2022/05/26 15:12:27 Benzinga
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB ) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment for ANAB has been Bearish. The signal from the volatility alert is trending Bearish . Therefore, the recommendation is to Strong Sell. The volatility alert was produced on the prior trading date, 5/25/2022, with a volatility change of +33.90%. The current volatility indicator stands at 7.237. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves the … Full story available on Benzinga.com
Looking For A Top Momentum Stock? Why AnaptysBio Inc. (NASDAQ: ANAB) Is A Great Pick 2022/05/14 18:00:00 Stocks Register
AnaptysBio Inc. (NASDAQ:ANAB) shares, rose in value on Friday, 05/13/22, with the stock price down by -0.38% to the previous day’s close as strong demand from buyers drove the stock to $21.13. Actively observing the price movement in the last trading, the stock closed the session at $21.21, falling within a range of $20.24 and … Looking For A Top Momentum Stock? Why AnaptysBio Inc. (NASDAQ: ANAB) Is A Great Pick Read More »
AnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08M 2022/05/04 21:41:48 Seeking Alpha
AnaptysBio press release (ANAB): Q1 GAAP EPS of -$1.31 misses by $0.32.Revenue of $0.97M (-91.4% Y/Y) misses by $4.08M.Shares -1.6% AH.Top-line data from the ongoing…
AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update 2022/05/04 20:15:00 GlobeNewswire
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the first quarter ended March 31, 2022 and provided pipeline updates.
AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers 2022/04/28 12:48:05 Benzinga
AnaptysBio Inc (NASDAQ: ANAB ) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody. Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials. ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed. The Company said that ANB032 demonstrated rapid … Full story available on Benzinga.com